Expert Highlights Immunotherapy Progress in Squamous Cell Lung Cancer – Targeted Oncology
Targeted Oncology |
Expert Highlights Immunotherapy Progress in Squamous Cell Lung Cancer
Targeted Oncology Beyond the May 2017 FDA approval of pembrolizumab (Keytruda) plus carboplatin/pemetrexed for nonsquamous patients regardless of PD-L1 status, researchers are turning their focus to immunotherapy combinations in squamous patients in ongoing … |
